Senti Operating Cycle from 2010 to 2026

SNTI Stock  USD 1.00  0.02  1.96%   
Senti Biosciences' Operating Cycle is increasing with slightly volatile movements from year to year. Operating Cycle is estimated to finish at 3,087 this year. For the period between 2010 and 2026, Senti Biosciences, Operating Cycle quarterly trend regression had mean deviation of  1,025 and range of 3.2 K. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
2.9 K
Current Value
3.1 K
Quarterly Volatility
1.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Senti Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senti Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 4.7 M or Selling General Administrative of 25.1 M, as well as many indicators such as Price To Sales Ratio of 16.18, Dividend Yield of 0.0 or PTB Ratio of 0.69. Senti financial statements analysis is a perfect complement when working with Senti Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Senti Stock
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.
The Operating Cycle trend for Senti Biosciences offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Senti Biosciences is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Senti Biosciences' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Senti Biosciences over the last few years. It is Senti Biosciences' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Senti Biosciences' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Senti Operating Cycle Regression Statistics

Arithmetic Mean961.82
Geometric Mean470.42
Coefficient Of Variation130.00
Mean Deviation1,025
Median334.94
Standard Deviation1,250
Sample Variance1.6M
Range3.2K
R-Value0.70
Mean Square Error853,403
R-Squared0.49
Significance0
Slope173.01
Total Sum of Squares25M

Senti Operating Cycle History

2026 3087.24
2025 2940.22
2023 3266.92
2022 69.53
2021 76.95
2020 293.67

About Senti Biosciences Financial Statements

Investors use fundamental indicators, such as Senti Biosciences' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Senti Biosciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Operating Cycle2.9 K3.1 K

Currently Active Assets on Macroaxis

When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is there potential for Biotechnology market expansion? Will Senti introduce new products? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.87)
Revenue Per Share
0.075
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.68)
Return On Equity
(3.95)
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Senti Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.